About the Test for Urology

About the Oncotype MAP Pan-Cancer Tissue Test

The management of advanced prostate cancer is evolving at a rapid pace, and Exact Sciences is here as your prostate cancer diagnostic partner.

Patients with advanced prostate cancer benefit from answers that provide clarity about appropriate therapy options and enable confident, timely treatment decisions. Patients who eventually progress on hormonal agents require reliable testing to determine eligibility for targeted therapeutic options. The Oncotype MAP Pan-Cancer Tissue Test can meet these demands by delivering comprehensive tumor profiling and identifying actionable genomic and proteomic alterations within 3-5 business days.*†

This test uses next-generation sequencing (NGS) and a broad array of tumor-specific and single immunohistochemical (IHC) stains to identify clinically relevant genomic alterations from patient specimens as small as 3 mm2 of tissue with 15% tumor content, about the size of a grain of rice.

Advantages of the Test for Advanced Prostate Cancer

✔  Actionable:
Informs eligibility for PARP Inhibitors and pembrolizumab as well as clinical trials
✔  Comprehensive:
Provides NGS (next-generation sequencing) on 250+ genes and IHC (immunohistochemical) results on 20+ protein markers
✔  Dynamic:
Reliable results quickly delivered with minimal tissue requirements

Optimizing Treatment for Advanced Prostate Cancer Patients

NCCN® guidelines§ recommend tumor testing in patients with metastatic prostate cancer to identify genomic alterations associated with targeted therapies. For example:

  • Homologous recombination repair (HRR) pathway gene alterations, which are found in 25-30 percent of metastatic castration-resistant prostate cancer (mCRPC) tumors, indicate that the use of poly (ADP-ribose) polymerase (PARP) inhibitors, platinum chemotherapy, or clinical trial inclusion may be appropriate.
  • Microsatellite instability-high (MSI-H) and mismatch repair deficiency (MMR-D) indicate that the use of pembrolizumab may be appropriate.
Oncotype MAP Pan-Cancer Tissue test reports are updated with new NCCN guideline recommendations and active clinical trials. This helps urologists stay up to date on the latest treatment options when determining crucial next steps for metastatic prostate cancer patients.

Why Choose the Oncotype MAP Pan-Cancer Tissue Test?

The Oncotype MAP Pan-Cancer Tissue Test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.


icon comprehensive

  • 257 Genes, 11 select fusions
  •   HHR gene mutations
  •   MSI/dMMR
  •   PD-L1
  •   TMB


icon actionable

NCCN/FDA-approved therapies
  •   NGS and IHC results for PARP inhibitors and immunotherapy
  •   Continuously updated to include enrolling clinical trials


icon accurate

Gold standard tissue testing for enhanced sensitivity
  •   Acceptable samples as small as 3mm2 with ≥15% tissue content
  •   Leverages a proprietary method designed for smaller specimens enabling a lower failure rate


icon fast

Results reported in 3-5 business days
  •   Designed to fit within existing workstreams
  •   QNS results in as few as 2 business days

Relevant Biomarkers for Advanced Prostate Cancer

Detected mutations and biomarkers Therapeutic options
HRR gene mutations BRCA1, BRCA2 PARP Inhibitors Olaparib and Rucaparib
ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, PALB2, RAD51C, RAD51D Olaparib
MSI-High MSI / MMR-Deficiency Checkpoint Inhibitor Pembrolizumab
MMR-Deficiency MLH1, MSH2, MSH6, PMS2
*≥10 mutations per megabase

Patient Eligibility

The Oncotype MAP Pan-Cancer Tissue Test is most appropriate for patients with advanced, metastatic, refractory, relapsed or recurrent cancer. The test can also provide valuable data and analysis to inform treatment decisions where no standard of care exists.

How to Interpret the Results

Learn more about the easy-to-interpret report with the resources below.

Oncotype MAP Pan-Cancer Tissue test focuses on therapy selection for today and captures emerging markers that may find their way into guidelines tomorrow.

*Data on File, In-house assay optimization protected by trade-secret and patent applications.
† Turnaround time is based on qualified sample receipt.
‡ Morris S, Subramanian J, Gel E, Runger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. https://doi.org/10.1371/journal.pone.0196556
§ https://www.nccn.org/

Making cancer care smarter.™